Company Overview and News
Anheuser-Busch InBev SA/NV (BUD - Free Report) , alias AB InBev, has been putting up a dismal show lately, owing to its dismal earnings trend. First-quarter 2018 marked AB InBev’s return to the negative earnings surprise trend, after a beat in the preceding quarter. While solid sales growth and synergies from cost savings continued to aid results, higher sales and marketing expenses ahead of the FIFA World Cup, along with fall in other operating income due to difficult comparisons, were impediments.
IPAR XEL BUD HSC ABI AHBIF SAM
The alcohol industry has seized on the trend for alcohol abstinence in Britain, where sales in 2017 of alcohol-free wine rose eight percent from 2015, according to consumer researcher Kantar Worldpanel. Image: Daniel LEAL-OLIVAS – AFP
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BUD 0168 ABI AHBIF MSCI
The underlying operating cash flows remain stable, and even after taking the higher capex into account, the dividend remains fully covered.
BT.A RDS.B RDS.A ELCPF BTGOF RDSB OCI RDSA BT ABI RYDBF OCINF RYDAF
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Enbridge (ENB) and CSX Corp. (CSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
GD ENB WM HUM SE ENB AVY ABI GM.WS.A GM.WS.B GM.WS.C CSX GM GM.WSB
Good morning and welcome to BT's Full-Year Results and Strategy Update Presentation. Presenting from the stage today is Jan du Plessis, Chairman of BT; Gavin Patterson, Chief Executive; and Simon Lowth, Chief Financial Officer. Also present are the CEOs of our customer-facing units. Before we begin, I need to let you know that there is no planned fire drill today. If you hear the alarm, listen for announcements and follow the instructions.
BT.A ABI BTGOF BT
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to EBR:ABI / AB INBEV on message board site Silicon Investor.